SynOx Therapeutics
Sander Veltkamp is currently serving as the Vice President External Affairs & Business Development at SynOx Therapeutics. Prior to this role, Sander held various positions in the pharmaceutical and healthcare industry, including Senior Medical Director at Gilead Sciences, Head of Medical Affairs Oncology at AbbVie, and Medical Lead Oncology/Hematology at Takeda. Sander's extensive experience also includes serving as a Board Member at Stichting Biowetenschappen en Maatschappij and Nederlandse Vereniging voor Farmaceutische Geneeskunde (NVFG). Sander holds a Ph.D. in Clinical Pharmacology and Translational Science from The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, as well as a PharmD in Pharmaceutical Sciences from Utrecht University.
This person is not in any teams
This person is not in any offices
SynOx Therapeutics
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.